Abstract
The central role of peroxisomes in ROS and lipid metabolism and their importance in brain functioning are well established. The aim of this work was to study the modulation of peroxisomal and peroxisome-related proteins in cortical neurons in vitro challenged with chronic or acute Aβ treatment, in order to investigate whether peroxisomes represent one of the cellular target of Aβ in these cells. The expression of peroxisomal (PMP70, catalase, acyl-CoA oxidase and thiolase), peroxisome-related (PPARα, insulin-degrading enzyme) and anti-oxidant (SOD1, SOD2, GSTP1) proteins was studied. The results obtained, demonstrating an early upregulation of the peroxisomal proteins during the chronic challenge, followed by their dramatic impairment after acute challenge, suggest that peroxisomes represent one of the first line of defence against Aβ-mediated oxidative injury. Our results support the notion that substances able to activate PPARα and/or to induce peroxisomal proliferation may constitute a novel preventive and/or therapeutic tool against neurodegenerative diseases.
Keywords: Neurodegeneration, lipid metabolism, anti-oxidant enzymes, PPARα
Current Alzheimer Research
Title: Neuronal Response of Peroxisomal and Peroxisome-Related Proteins to Chronic and Acute Aβ Injury
Volume: 6 Issue: 3
Author(s): A. Cimini, E. Benedetti, B. D'Angelo, L. Cristiano, S. Falone, S. Di Loreto, F. Amicarelli and M. P. Ceru
Affiliation:
Keywords: Neurodegeneration, lipid metabolism, anti-oxidant enzymes, PPARα
Abstract: The central role of peroxisomes in ROS and lipid metabolism and their importance in brain functioning are well established. The aim of this work was to study the modulation of peroxisomal and peroxisome-related proteins in cortical neurons in vitro challenged with chronic or acute Aβ treatment, in order to investigate whether peroxisomes represent one of the cellular target of Aβ in these cells. The expression of peroxisomal (PMP70, catalase, acyl-CoA oxidase and thiolase), peroxisome-related (PPARα, insulin-degrading enzyme) and anti-oxidant (SOD1, SOD2, GSTP1) proteins was studied. The results obtained, demonstrating an early upregulation of the peroxisomal proteins during the chronic challenge, followed by their dramatic impairment after acute challenge, suggest that peroxisomes represent one of the first line of defence against Aβ-mediated oxidative injury. Our results support the notion that substances able to activate PPARα and/or to induce peroxisomal proliferation may constitute a novel preventive and/or therapeutic tool against neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Cimini A., Benedetti E., D'Angelo B., Cristiano L., Falone S., Di Loreto S., Amicarelli F. and Ceru P. M., Neuronal Response of Peroxisomal and Peroxisome-Related Proteins to Chronic and Acute Aβ Injury, Current Alzheimer Research 2009; 6 (3) . https://dx.doi.org/10.2174/156720509788486518
DOI https://dx.doi.org/10.2174/156720509788486518 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Endothelial Dysfunction Induced by Cadmium and Mercury and its Relationship to Hypertension
Current Hypertension Reviews Serum Amyloid Beta Peptides in Patients with Dementia and Age-Matched Non-Demented Controls as Detected by Surface-Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry (SELDI-TOF MS)
Current Clinical Pharmacology Editorial (Thematic Issue: Neuroglia in Alzheimer’s Disease: From Cohort to Contestant in the Disease Progression and its Therapy)
Current Alzheimer Research Editorial (Thematic Issue: Mechanisms of Atherogenesis and Development of Anti-Atherosclerotic Therapy)
Current Pharmaceutical Design Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) HIV Associated Neurodegenerative Disorders: A New Perspective on the Role of Lipid Rafts in Gp120-Mediated Neurotoxicity
Current HIV Research Follow-Up Study of Olfactory Deficits, Cognitive Functions, and Volume Loss of Medial Temporal Lobe Structures in Patients with Mild Cognitive Impairment
Current Alzheimer Research The Unbiased Search of Biomarkers in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology The Prevalence, Morbidities, and Treatments of Insomnia
CNS & Neurological Disorders - Drug Targets MicroRNAs: Emerging Role in the Endogenous μ Opioid System
CNS & Neurological Disorders - Drug Targets Novel Technologies for Dipeptide Drugs Design and their Implantation
Current Pharmaceutical Design Beneficial Effects of Lysosome-Modulating and Other Pharmacological and Nanocarrier Agents on Amyloid-beta-treated Cells
Current Pharmaceutical Biotechnology Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design The MMP-2/TIMP-2 System in Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Adult Stem Cell Transplantation in Stroke: Its Limitations and Prospects
Current Stem Cell Research & Therapy Generation and Transplantation of Dopaminergic Neurons Derived from Embryonic Stem Cells
Current Stem Cell Research & Therapy